Vascular- and Immuno-Metabolism as Drivers of Cardiovascular Disease: Insights Obtained from Omics Approaches

Know about the book -

Vascular- and Immuno-Metabolism as Drivers of Cardiovascular Disease: Insights Obtained from Omics Approaches is written by Yvonne Döring and published by Frontiers Media SA. It's available with International Standard Book Number or ISBN identification 2832559948 (ISBN 10) and 9782832559949 (ISBN 13).

Despite achievements in the management of cardiovascular disease (CVD) over the last 50 years, CVD remains a primary cause of global morbidity and mortality in both emerging and developed economies. Due to the rising aging population in combination with an increase in cardiometabolic risk factors, the number of individuals affected by CVD is currently on the rise. Therefore, it is of utter importance to develop new strategies aimed at reducing CVD risk and elucidate the molecular mechanisms and important players of CVD, including atherosclerosis and plaque rupture and erosion. Over the past years, it became evident that a specific CVD, atherosclerosis, is a multifactorial disease that is not only driven by lipids but also by inflammation. Compelling evidence that inflammation and the immune system play a crucial role in atherosclerotic CVD was provided by the landmark Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS), performed in 2017. Here it was shown that a monoclonal antibody targeting interleukin-1b (IL-1b), termed Canakinumab, effectively reduced CVD risk and mortality, especially in patients characterized with residual inflammation. This effect was independent of lipid-level lowering. In late 2019, the inflammation hypothesis of atherosclerosis was confirmed in the Colchicine Cardiovascular Outcomes Trial (COLCOT), using the anti-inflammatory agent colchicine in patients with recent myocardial infarction. A follow-up study in 2020 applying colchicine in a randomized trial involving patients with chronic coronary disease (LoDoCo), also showed significant risk reduction. These landmark studies set the stage for identifying drug targets that block atherosclerosis-specific inflammatory pathways as a highly promising strategy to reduce cardiovascular risk.